NCT02829307View on ClinicalTrials.gov

A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 23, 2016

Primary Completion Date

January 27, 2017

Study Completion Date

January 27, 2017

Conditions
Drug-Related Side Effects and Adverse Reactions
Interventions
DRUG

89Zr-GSK3128349 1 mg

89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.

Trial Locations (1)

9471 GP

GSK Investigational Site, Zuidlaren

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

PRA Health Sciences for clinical study conduct.

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT02829307 - A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter